COMPANY PROFILE

Carrick Therapeutics

Explore full profile

Transformative Cancer Medicines

Dublin, IrelandFounded 2015Biotech & Life Sciences

Valuation $250–500M Last recorded · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Carrick Therapeutics

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Dublin, Ireland
Employees: 16
Open positions: None listed
Dealroom signal: 75.4/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Analytics, Biotechnology, Oncology, Medical & Healthcare, Chemotherapy, Spinout, Biotech and Pharma, Cancer Care Companion, biotech medtech and e-health, Woman Founder
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VCOther financing	Dec 2022	$35M	$475M	Pfizer	↗
SERIES COther financing	Dec 2022	$25M	$475M	GV · Evotec · Lightstone Ventures · ARCH Venture Partners	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Carrick Therapeutics website traffic

Latest recorded traffic for Carrick Therapeutics is 2.4K monthly website visits, down 11.1% over the last three months. Carrick Therapeutics's team grew 0% over the past year.

Latest monthly visits2.4K 3-month web change-11.1% 1-year team growth0%

Monthly website visitsJan 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
SBStroma BiosciencesTargeting the stroma microenvironment to sensitise cancers to chemotherapeutics ‘Spatial Synthetic Lethality’	Cambridge, United Kingdom	Low Activity
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational
SPSpireaAdvanced antibody-drug conjugate technology for cancer therapeutics	Harrogate, United Kingdom	Operational
ITIGEM TherapeuticsImmuno-oncology IgE antibodies for treating solid tumors	London, United Kingdom	Operational
ELElasmogenNext generation therapeutic biologics company discovering and developing drugs	Aberdeen, United Kingdom	Operational
THTheolyticsOncolytic adenovirus therapies for intravenous cancer treatment	Oxford, United Kingdom	Operational
EXExonateTopical small-molecule therapeutics for retinal vascular diseases	Cambridge, United Kingdom	Operational